TY - JOUR T1 - Characteristics of a real world cohort of Canadians treated with benralizumab JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA3726 VL - 58 IS - suppl 65 SP - PA3726 AU - Stephen G Noorduyn AU - Mackenzie A Hamilton AU - Brett Lancaster AU - Alain Gendron AU - Lawrence Mbuagbaw AU - Erika Penz Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA3726.abstract N2 - Background: Nearly 8% of patients with asthma in Canada have severe disease (Asthma Canada, 2014). Phenotyping may be required to determine dominant profile prior to treatment with a biologic therapy. Benralizumab is an anti-IL-5Rα biologic used as add-on maintenance therapy for severe eosinophilic asthma.Objective: To describe the characteristics of patients initiating benralizumab for severe eosinophilic asthma in the real world setting.Methods: This is an early analysis of the POWER study (NCT03833141), part of the XALOC multi-country study program. Eligible patients were recruited from 23 clinics in Canada if they had blood eosinophils ≥300c/µL, total Asthma Control Questionnaire (ACQ-6) score ≥1.5, and were benralizumab naïve. Baseline data include patient sociodemographic data and self-reported asthma control, disease severity, and quality of life (QoL).Results: As of Jan 2021, 78 of 200 individuals had completed a baseline assessment. Mean (standard deviation; SD) age at entry was 55(16) years and 72% were female. At baseline 28% of patients report active OCS use.The baseline mean(SD) ACQ-6 score was 3.18(0.98). Most patients rated their asthma severity as moderate and reported a median (interquartile range) of 3 (2-4) exacerbations in the prior year. Mean (SD) utility and global health rating on the EQ-5D-5L visual analogue scale were 0.61(0.34) and 56.88(20.12) respectively.Conclusions: At baseline, patients view their asthma as moderate severity but demonstrate poor control, frequent exacerbations, and meet clinical criteria for severe disease. Patients showed disease-related impairment and overall lower QoL at baseline relative to the average Canadian utility score of 0.86 (Guertin, 2018).FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3726.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -